Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Total Current Liabilities: 2016-2025

Historic Total Current Liabilities for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $452.9 million.

  • Collegium Pharmaceutical's Total Current Liabilities fell 1.41% to $452.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $452.9 million, marking a year-over-year decrease of 1.41%. This contributed to the annual value of $509.5 million for FY2024, which is 11.27% up from last year.
  • According to the latest figures from Q3 2025, Collegium Pharmaceutical's Total Current Liabilities is $452.9 million, which was down 2.51% from $464.6 million recorded in Q2 2025.
  • Collegium Pharmaceutical's Total Current Liabilities' 5-year high stood at $509.5 million during Q4 2024, with a 5-year trough of $226.8 million in Q2 2021.
  • Moreover, its 3-year median value for Total Current Liabilities was $459.4 million (2024), whereas its average is $459.2 million.
  • In the last 5 years, Collegium Pharmaceutical's Total Current Liabilities declined by 10.02% in 2021 and then spiked by 82.99% in 2022.
  • Collegium Pharmaceutical's Total Current Liabilities (Quarterly) stood at $279.6 million in 2021, then skyrocketed by 55.14% to $433.7 million in 2022, then increased by 5.58% to $457.9 million in 2023, then climbed by 11.27% to $509.5 million in 2024, then decreased by 1.41% to $452.9 million in 2025.
  • Its last three reported values are $452.9 million in Q3 2025, $464.6 million for Q2 2025, and $486.7 million during Q1 2025.